$TEM

Fukushima Ryan sold $1.9M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 33,284 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $57.39 ($56.80–$59.47, $1.91M total) across 4 trades on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Jul 10, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size, execution window (July 8), and the fact it was conducted under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh datapoint on insider liquidity and potential sentiment, but the 10b5-1 structure limits fundamental inference.

03

What to watch

Traders may want to compare this sale to prior insider activity cadence and whether other executives filed similar 10b5-1 sales around the same dates.

Relevance 5/10Novelty 5/10Timing: Filed July 10, covering sales executed July 8.

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc., reported by CEO Data Fukushima Ryan.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO Fukushima Ryan sold $1.91M of TEM shares via a Rule 10b5-1 plan, with 33,284 shares sold at $56.80–$59.47.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other negative catalysts emerge.

Evidence & confidence

The filing is a primary Form 4 disclosure and the transaction size is meaningful, but the article specifies it was pre-arranged under Rule 10b5-1, reducing interpretive weight.

Market effects

Minimal sector read-through; this is company-specific insider transaction disclosure rather than a sector catalyst.

No clear regional spillover implied by the filing details.

No global macro or cross-border transaction effects indicated.

Counterpoint

Because the sale is 10b5-1 pre-arranged, it may reflect routine liquidity needs rather than bearish fundamentals, so the market reaction could be overstated.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider sale disclosure (TEM).

  • Fukushima Ryan

    CEO, Data, who reported an indirect open-market sale under a Rule 10b5-1 plan.

Related articles

$TEMMed

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.